You are here

Samsca

Palladio bags $20 million Series B to topple a problematic kidney disease drug

Endpoints

Fri, 09/25/20 - 10:33 am

Palladio Biosciences

autosomal dominant polycystic kidney disease

FDA warns of liver injury risk associated with hyponatremia drug

Healio

Sun, 01/27/13 - 11:33 am